Global Markets Direct’s, 'Chronic Inflammation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Inflammation. Chronic Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Chronic Inflammation. - A review of the Chronic Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Inflammation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammation. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Chronic Inflammation pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Chronic Inflammation - Pipeline Review, H2 2013 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Chronic Inflammation Overview 7 Therapeutics Development 8 An Overview of Pipeline Products for Chronic Inflammation 8 Chronic Inflammation Therapeutics under Development by Companies 10 Chronic Inflammation Therapeutics under Investigation by Universities/Institutes 12 Early Clinical Stage Products 13 Comparative Analysis 13 Discovery and Pre-Clinical Stage Products 14 Comparative Analysis 14 Chronic Inflammation Therapeutics - Products under Development by Companies 15 Chronic Inflammation Therapeutics - Products under Investigation by Universities/Institutes 16 Companies Involved in Chronic Inflammation Therapeutics Development 17 Italfarmaco S.p.A. 17 Phenex Pharmaceuticals AG 18 Anacor Pharmaceuticals, Inc. 19 Reata Pharmaceuticals, Inc. 20 Dynamis Therapeutics, Inc. 21 Biolink Group AS 22 Dompe Farmaceutici S.p.A. 23 KAEL-GemVax 24 Biocure pharm 25 Chronic Inflammation - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 tertomotide - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 DF-2156A - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 CIF-C/D-3G - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 Retinoid-Acid Receptor Related Orphan Receptor Gamma T Program - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 Tumor Necrosis Factor Receptor 25 Antagonists - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 AN-3485 - Drug Profile 37 Product Description 37 Mechanism of Action 37 RandD Progress 37 AIMs For Chronic Inflammation - Drug Profile 38 Product Description 38 Mechanism of Action 38 RandD Progress 38 BCP-1071 - Drug Profile 39 Product Description 39 Mechanism of Action 39 RandD Progress 39 MCP-1 - Drug Profile 40 Product Description 40 Mechanism of Action 40 RandD Progress 40 TACE Inhibitory Protein - Drug Profile 41 Product Description 41 Mechanism of Action 41 RandD Progress 41 Anti-Alpha Epsilon Beta-7 - Drug Profile 42 Product Description 42 Mechanism of Action 42 RandD Progress 42 VAC-03 - Drug Profile 43 Product Description 43 Mechanism of Action 43 RandD Progress 43 DYN-15 - Drug Profile 44 Product Description 44 Mechanism of Action 44 RandD Progress 44 Drug For Chronic Inflammation - Drug Profile 45 Product Description 45 Mechanism of Action 45 RandD Progress 45 TAT-SNAP-23 - Drug Profile 46 Product Description 46 Mechanism of Action 46 RandD Progress 46 N-Acylethanolamine Acid Amidase Inhibitors - Drug Profile 47 Product Description 47 Mechanism of Action 47 RandD Progress 47 Chronic Inflammation Therapeutics - Drug Profile Updates 48 Chronic Inflammation Therapeutics - Dormant Products 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 52 Disclaimer 52
List of Tables
Number of Products Under Development for Chronic Inflammation, H2 2013 8 Products under Development for Chronic Inflammation - Comparative Analysis, H2 2013 9 Number of Products under Development by Companies, H2 2013 11 Number of Products under Investigation by Universities/Institutes, H2 2013 12 Comparative Analysis by Early Clinical Stage Development, H2 2013 13 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14 Products under Development by Companies, H2 2013 15 Products under Investigation by Universities/Institutes, H2 2013 16 Italfarmaco S.p.A., H2 2013 17 Phenex Pharmaceuticals AG, H2 2013 18 Anacor Pharmaceuticals, Inc., H2 2013 19 Reata Pharmaceuticals, Inc., H2 2013 20 Dynamis Therapeutics, Inc., H2 2013 21 Biolink Group AS, H2 2013 22 Dompe Farmaceutici S.p.A., H2 2013 23 KAEL-GemVax, H2 2013 24 Biocure pharm, H2 2013 25 Assessment by Monotherapy Products, H2 2013 26 Assessment by Stage and Route of Administration, H2 2013 28 Assessment by Stage and Molecule Type, H2 2013 30 Chronic Inflammation Therapeutics - Drug Profile Updates 48 Chronic Inflammation Therapeutics - Dormant Products 50
List of Figures
Number of Products under Development for Chronic Inflammation, H2 2013 8 Products under Development for Chronic Inflammation - Comparative Analysis, H2 2013 9 Products under Development by Companies, H2 2013 10 Products under Investigation by Universities/Institutes, H2 2013 12 Early Clinical Stage Products, H2 2013 13 Discovery and Pre-Clinical Stage Products, H2 2013 14 Assessment by Monotherapy Products, H2 2013 26 Assessment by Route of Administration, H2 2013 27 Assessment by Stage and Route of Administration, H2 2013 28 Assessment by Molecule Type, H2 2013 29 Assessment by Stage and Molecule Type, H2 2013 30
Italfarmaco S.p.A. Phenex Pharmaceuticals AG Anacor Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc. Dynamis Therapeutics, Inc. Biolink Group AS Dompe Farmaceutici S.p.A. KAEL-GemVax Biocure pharm